Joint Clinical Trials Office

You are here

TARGET–PBC: A 5-year Longitudinal Observational Study of Patients with Primary Biliary Cholangitis

Clinical Trial Details

This is an observational study. This study is for men and women who have Primary Biliary Cholangitis (PBC), which is a chronic, or long-term, disease of the liver characterized by damaged bile ducts due to inflammation. Bile is a digestive liquid that is made in the liver that helps the small intestines digest fats and fatty vitamins. 

The purpose of this study to observe any treatment for PBC in a large number of people in a “real life” setting. Researchers are interested in observing how these treatments, lifestyle changes, and counseling work in patients who are treated by their doctors in routine practice. Any treatments for PBC will be chosen by the participant and the study doctor. No specific treatments will be prescribed just by participating in this study. 
If an individual agrees to participate in this study, their past (up to 3 years before) and future (up to 5 years) medical records will be collected. 
In addition, participants will have the opportunity to participate in optional portions in this study: 

  • Optional blood sample collection 
  • Optional questionnaire 
  • Optional Substudy 

Participation in the study will last for up to 5 years. 

Participants will be reimbursed for their time. 

Key Eligibility: 
  • Men and women who are 18 and over 
  • Have been diagnosed with PBC
  • Detailed eligibility reviewed when contacting the study team 

Study contact by location

Upper East Side - Manhattan


Mallory Ianelli, RN, BSN
(646) 962-4040

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:




Open to Enrollment

Age Group